Akash Maniam, MD MBA’s Post

MammaPrint can accurately identify which patients with HR+ early-stage breast cancer benefit from extending endocrine therapy

“By changing the architecture of the ECM to allow for better drug penetration, the LOX inhibitor enables the chemotherapy to stress the tumor into producing more reactive oxygen species (ROS) more effectively. At high enough levels, ROS creates DNA damage that can lead to cell death. Importantly, inhibiting LOX also blocks focal adhesion kinase (FAK) signaling, which would otherwise promote DNA repair. Taken together, these effects can overcome chemotherapy resistance. Further, these effects were found in different types of models, including triple-negative breast cancer cell lines, in vivo models and organoid models created from patient-derived xenografts.” #cancer #breastcancer #cancerresearch #triplenegativebreastcancer #DNArepair #protemics #DNArepair #tumor

The frequent overexpression of prostate-specific membrane antigen (PSMA) in prostate cancers opened the way for the development of tracers for diagnostic purposes and for therapeutic applications, thereby offering a more precise and personalised approach for the treatment of castration-resistant tumours. #cancer #oncology #PSMA #ProstateCa #enzalutamide

🌟💬 Xtalks Spotlight: In oncology diagnostics, distinguishing clonal hematopoiesis from tumor cell mutations is crucial to avoid diagnostic and treatment errors. We spoke with Dr. Karina Eterovic, R&D Director, Oncology Diagnostics, Eurofins Viracor BioPharma Services, about how genomic profiling accomplishes this. ⏩ Watch and read the full interview with Dr. Eterovic here: https://buff.ly/4dUcnaS #Oncology #ClinicalOncology #Cancer #CancerGenetics #PrecisionMedicine

⚡️ Advancing precision oncology in urothelial cancer: Pre-treatment metastatic biopsies capture real-time tumor biology, addressing heterogeneity missed in primary samples. This approach enhances prediction of response to therapies like enfortumab vedotin and FGFR inhibitors, guiding better treatment choices for patients with metastatic urothelial cancer. #BladderCancer https://buff.ly/3YK9Drj.

📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Why Tumor Naming Has to Change There is a growing disconnect between classifying cancers according to the organ in which the tumor originated and developments in precision oncology, which uses the molecular profiling of tumor and immune cells to guide therapies. Read more on our blog: https://lnkd.in/dzFjuwe9

Characterisation of acquired mechanisms of resistance to PARP inhibitors Daniel Stover #AnnalsOfOncology #Cancer #OncoDaily #Oncology #CancerCare

Working in Oncology? Learn how the ClinoStar promotes uniform cell aggregation resulting in consistent tumoroid size and structure. #celvivo #cellculture #onclolgy #tumoroids #cancer https://lnkd.in/eRmHJP7e

#LegendCapital #PortfolioNews Our portfolio company, Innovent Biologics, presented clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer at the 2024 ESMO - European Society for Medical Oncology, a globally recognized authority in oncology. This cutting-edge treatment offers significant results for advanced colorectal cancer. Currently, Innovent Biologics is conducting Phase 1/2 clinical trials in China, the United States, and Australia to evaluate the safety, tolerability and efficacy of IBI363 in subjects with advanced solid tumors. With ongoing studies in other tumor types, IBI363 demonstrates promising potential to improve patient outcomes worldwide. #InnoventBiologics #IBI363 #ESMO2024 #Biopharma #Oncology